Initial real-world experience with ribociclib in advanced breast cancer
Journal of Oncology Pharmacy Practice
Published online on February 18, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
PurposeCDK4/6 inhibitors, such as ribociclib, are recommended in combination with hormonal therapy to treat advanced/metastatic hormone receptor-positive, HER2-negative breast cancer. The objectives of this study are to evaluate the therapeutic outcome ...
PurposeCDK4/6 inhibitors, such as ribociclib, are recommended in combination with hormonal therapy to treat advanced/metastatic hormone receptor-positive, HER2-negative breast cancer. The objectives of this study are to evaluate the therapeutic outcome ...